A new therapeutic target for metastatic and resistant prostate cancers

(IDIBELL-Bellvitge Biomedical Research Institute) Researchers from IDIBELL and ICO showed that the most aggressive prostate tumors generate increasing levels of the NSD2 protein, which are related to tumor progression and therapeutic resistance.NSD2 inhibition could lead to the re-sensitization of those prostate tumors resistant to conventional antiandrogenic treatments.The study suggests an innovative, combined therapeutic approach that would include the administration of a NSD2 inhibitor drug together with conventional antiandrogenic drugs.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news